FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). |
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
PUMA BIOTECHNOLOGY, INC. [ PBYI ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
3. Date of Earliest Transaction
(Month/Day/Year) 02/17/2021 | ||||||||||||||||||||||||||
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
COMMON STOCK | 02/17/2021 | A | 149,951(1)(2) | A | $0.00 | 4,432,987 | D |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
STOCK OPTION (RIGHT TO BUY) | $12.02 | 02/17/2021 | A | 210,944 | (3)(4) | 02/16/2031 | COMMON STOCK | 210,944 | $0.00 | 210,944 | D |
Explanation of Responses: |
1. Subject to the Grantee's continued status as an Employee, the Restricted Stock Units shall vest with respect to (i) one-third (1/3rd) of the Restricted Stock Units on the first anniversary of the vesting commencement date of January 1, 2021 (the "Vesting Commencement Date"), and (ii) one-sixth (1/6th) of the Restricted Stock Units on each of July 1, 2022, January 1, 2023, July 1, 2023 and January 1, 2024; provided, however, that if the Grantee experiences a Termination of Service by the Company without Cause or by the Grantee with Good Reason (each as defined in Mr. Auerbach's employment agreement), in either case, during the period beginning sixty (60) days prior to and ending eighteen (18) months after the occurrence of a Change in Control, then (subject to timely executing and not revoking the Release Agreement (as defined in the employment agreement)) the Restricted Stock Units shall vest in full on the later to occur of such termination or the Change in Control. (See footnote 2) |
2. (continued from Footnote 1 above) Unless otherwise defined herein, the terms used herein have the same defined meanings as in the Restricted Stock Unit Agreement. |
3. Subject to the Optionee's continued status as an Employee, the Option shall vest and become exercisable with respect to (i) one-third (1/3rd) of the Shares subject thereto on the first anniversary of January 1, 2021 (the "Vesting Commencement Date"), and (ii) one-sixth (1/6th) of the Shares subject thereto on each of July 1, 2022, January 1, 2023, July 1, 2023, and January 1, 2024; provided, however, that if the Optionee experiences a Termination of Service by the Company without Cause or by the Optionee with Good Reason (each as defined in Mr. Auerbach's employment agreement), in either case, during the period beginning sixty (60) days prior to and ending eighteen (18) months after the occurrence of a Change in Control, then (subject to timely executing and not revoking the Release Agreement (as defined in the employment agreement)) (i) the Option shall vest and become exercisable in full on the later to occur of such termination or the Change in Control, and (continued in footnote 4) |
4. (continued from footnote 3 above) (ii) the Option shall remain exercisable until the earlier to occur of the first anniversary of such termination or the Expiration Date. Unless otherwise defined herein, the terms used herein have the same defined meanings as in the Stock Option Agreement. |
Remarks: |
/s/ Alan H. Auerbach | 02/19/2021 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |